Mayne Pharma to divest International segment for $55.5m

Summary by 6ix AI

Mayne Pharma Group Ltd. has announced the divestment of its international segment to Evaris Pharma for a significant cash consideration, marking a strategic shift for the company. The transaction is structured as a share sale and is expected to complete in the third quarter of the fiscal year, pending customary conditions. This move will allow Mayne Pharma to focus entirely on its U.S. operations in women's health and dermatology, enhancing its growth strategy. The sale includes a supply agreement to ensure continuity of certain products for U.S. patients.

Written by 6ix AI from the company’s filing. How 6ix writes summaries